Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Mary B. Callanan, Caroline Milin, Marie-Helene Delfau-Larue, Clément Bailly, Clémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, Emmanuel Gyan, Krimo Bouabdallah, Remy Gressin, Gandhi Damaj, Olivier Casasnovas, Vincent Ribrag, Samuel Griolet, Barbara Burroni, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2024-208081

Published: 2024

Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart

Blood (2024) 144 (Supplement 1): 745.

https://doi.org/10.1182/blood-2024-194357

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Jimena Castorena, Christophe Desterke, Barbara Burroni, Lise Willems, Marie-Caroline Le Bousse-Kerdilès, Laurence Legros, Laura Velazquez

Blood (2024) 144 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2024-210924

Published: 2024

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Blood (2024) 143 (11): 983–995.

https://doi.org/10.1182/blood.2023021564

Published: 2024

Includes: Supplemental data

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Alexandra Traverse-Glehen, Laurent Martin, Camille Laurent, Peggy Dartigues, Barbara Burroni, Diane Damotte, Marie Parrens, Herve Ghesquieres, Marguerite Fournier, Salim Kanoun, Anne Ségolène Cottereau, Marc Andre, Cédric Rossi, René-Olivier Casasnovas

Blood (2023) 142 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2023-174784

Published: 2023

Journal Articles

RCHOP Plus High-Dose Methotrexate As First-Line Therapy in Large B-Cell Lymphoma with Testis Involvement

Raphaël Liévin, Barbara Burroni, Patricia Palmic, Estelle Balducci, Justine Decroocq, Benedicte Deau Fischer, Patricia Franchi, Marguerite Vignon, Jérémie Zerbit, Anne Ségolène Cottereau, Sophie Kaltenbach, Ludovic Lhermitte, Didier Bouscary, Lise Willems

Blood (2023) 142 (Supplement 1): 6086.

https://doi.org/10.1182/blood-2023-186832

Published: 2023

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Michal Szymczyk, Catherine Thieblemont, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hübel, Barbara Burroni, Wolfram Klapper, Michael Unterhalt, Eva Hoster, Martin Dreyling

Blood (2021) 138 (Supplement 1): 380.

https://doi.org/10.1182/blood-2021-150181

Published: 2021

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Barbara Burroni, Anne Moreau, MD, Mathieu Baldacini, MD, Antoine Martin, MD PhD, Steven Le Gouill, Vincent Ribrag, Rémy Gressin, MD, Chantal Brochet, Martin H. Dreyling, MD PhD, Samuel Griolet, Yannick Le Bris, PharmD, Morgane Cheminant, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Luc Mathieu Fornecker, MD PhD, Alexandra Traverse-Glehen, MD PhD, Danielle Canioni, MD

Blood (2019) 134 (Supplement_1): 2820.

https://doi.org/10.1182/blood-2019-129790

Published: 2019

Journal Articles

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Blood (2018) 132 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2018-99-113303

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma

Christina Kanaan, Barbara Burroni

Blood (2018) 132 (16): 1725.

https://doi.org/10.1182/blood-2018-07-862524

Published: 2018

Journal Articles

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Alexandra traverse-Glehen, MD PhD, Antoine Martin, MD PhD, Remy Gressin, MD, Vincent Ribrag, MD, Catherine Thieblemont, MD PhD, Marie-Helene Delfau-Larue, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Mary Callanan, MD, Steven Le Gouill, MDPhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 4036.

https://doi.org/10.1182/blood.V130.Suppl_1.4036.4036

Published: 2017

Journal Articles

Efficacy and Safety of Intensive Etoposide Aracytine Consolidation Following Rituximab Methotrexate Temozolomide Induction in Newly Diagnosed Primary Central Nervous System Lymphoma

Blood (2017) 130 (Supplement 1): 1573.

https://doi.org/10.1182/blood.V130.Suppl_1.1573.1573

Published: 2017

NARROW

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

RCHOP Plus High-Dose Methotrexate As First-Line Therapy in Large B-Cell Lymphoma with Testis Involvement

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

Efficacy and Safety of Intensive Etoposide Aracytine Consolidation Following Rituximab Methotrexate Temozolomide Induction in Newly Diagnosed Primary Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only